Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics

PLoS One. 2015 Jun 24;10(6):e0130829. doi: 10.1371/journal.pone.0130829. eCollection 2015.

Abstract

The respiratory syncytial virus (RSV) fusion protein F is considered an attractive vaccine candidate especially in its prefusion conformation. We studied whether recombinant soluble RSV F proteins could be stabilized in a prefusion-like conformation by mutation of heptad repeat B (HRB). The results show that soluble, trimeric, non-cleaved RSV F protein, produced by expression of the furin cleavage site-mutated F ectodomain extended with a GCN4 trimerization sequence, is efficiently recognized by pre- as well as postfusion-specific antibodies. In contrast, a similar F protein completely lacking HRB displayed high reactivity with prefusion-specific antibodies recognizing antigenic site Ø, but did not expose postfusion-specific antigenic site I, in agreement with this protein maintaining a prefusion-like conformation. These features were dependent on the presence of the GCN4 trimerization domain. Absence of cleavage also contributed to binding of prefusion-specific antibodies. Similar antibody reactivity profiles were observed when the prefusion form of F was stabilized by the introduction of cysteine pairs in HRB. To study whether the inability to form the 6HB was responsible for the prefusion-like antibody reactivity profile, alanine mutations were introduced in HRB. Although introduction of alanine residues in HRB inhibited the formation of the 6HB, the exposure of postfusion-specific antigenic site I was not prevented. In conclusion, proteins that are not able to form the 6HB, due to mutation of HRB, may still display postfusion-specific antigenic site I. Replacement of HRB by the GCN4 trimerization domain in a non-cleaved soluble F protein resulted, however, in a protein with prefusion-like characteristics, suggesting that this HRB-lacking protein may represent a potential prefusion F protein subunit vaccine candidate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / pharmacology
  • Antibodies, Viral / pharmacology*
  • Binding Sites
  • Cell Line, Tumor
  • Epithelial Cells / metabolism*
  • Epithelial Cells / pathology
  • Epithelial Cells / virology
  • Gene Expression
  • HEK293 Cells
  • Humans
  • Models, Molecular
  • Protein Binding
  • Protein Multimerization
  • Protein Structure, Tertiary
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Respiratory Mucosa / metabolism*
  • Respiratory Mucosa / pathology
  • Respiratory Mucosa / virology
  • Respiratory Syncytial Virus, Human / genetics*
  • Respiratory Syncytial Virus, Human / metabolism
  • Viral Fusion Proteins / antagonists & inhibitors
  • Viral Fusion Proteins / chemistry
  • Viral Fusion Proteins / genetics*
  • Viral Fusion Proteins / metabolism

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Recombinant Proteins
  • Viral Fusion Proteins

Grants and funding

This study was funded in part by Mucosis B. V. No additional external funding was received for this study. We agree that the funder provided support in the form of salaries for authors [IW, AR, KL, BJH], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.